Reassessing pembrolizumab dosing in NSCLC for methodological and clinical accuracy

IF 4.5 2区医学 Q1 ONCOLOGY Lung Cancer Pub Date : 2024-10-09 DOI:10.1016/j.lungcan.2024.107989

Da Qiu , Chao Qiu , Yongneng Wang , Dan Shan

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

重新评估 NSCLC 中 pembrolizumab 剂量的方法学和临床准确性

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Lung Cancer 医学-呼吸系统

CiteScore

9.40

自引率

3.80%

发文量

407

审稿时长

25 days

期刊介绍： Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.

期刊最新文献

Addressing knowledge and attitude barriers to lung cancer screening: Development and evaluation of web-based decision aid Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future care The molecular subtypes of small cell lung cancer defined by key transcription factors and their clinical significance Radiological follow-up in patients with resected pulmonary carcinoids: Should we reduce radiation exposure? Diagnostic performance of Shape-Sensing Robotic-Assisted bronchoscopy with mobile Cone-Beam CT for cystic and cavitary pulmonary lesions